Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04818970 · ClinicalTrials.gov registry record · NA

Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients

A NA study of Covid19 and Autoimmune Diseases, sponsored by Cytokind.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT04818970 is a NA study of Covid19 and Autoimmune Diseases that has completed, run by Cytokind. The registered enrollment target is 30 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04818970, a NA study of Covid19 and Autoimmune Diseases, has completed, sponsored by Cytokind.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study to evaluate the translational application of the safe and effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in an effort to improve their immune and hemostatic imbalance to increase survival and improve outcomes.

Interventions

  • DEVICE Narrow Band ultraviolet B-Band Light
  • DEVICE non Narrow Band ultraviolet B-Band Light

Study Locations (1)

Louisiana

  • West Jefferson Medical Center and LSUHSC-NO - New Orleans

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-05-21
Est. Completion 2021-12-01
Phase NA

Sponsor

Cytokind

1 total trials

What the Registry Record Tells You About NCT04818970

The ClinicalTrials.gov registry entry for NCT04818970 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (99% lower). The listed sponsor is Cytokind, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Narrow Band ultraviolet B-Band Light is the first listed.

NCT04818970 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.

Frequently Asked Questions

What is clinical trial NCT04818970 about?

NCT04818970 is a clinical study titled "Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients". The purpose of this study to evaluate the translational application of the safe and effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in an effort to improve their immune and hemostatic imbalance to increase survival and improve outcomes.

What is the current status of trial NCT04818970?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-05-21. Estimated completion is 2021-12-01.

What conditions does trial NCT04818970 study?

This clinical trial studies the following conditions: Covid19, Autoimmune Diseases, Corona Virus Infection, Coagulation Disorder, Blood.

What interventions are being tested in trial NCT04818970?

The interventions under investigation include: Narrow Band ultraviolet B-Band Light (DEVICE), non Narrow Band ultraviolet B-Band Light (DEVICE).

Who is sponsoring clinical trial NCT04818970?

This trial is sponsored by Cytokind, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04818970 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Covid19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.